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Ivacaftor, the first cystic fibrosis (CF) transmembrane conductance regulator (CFTR) 
potentiator provides a remarkable example of personalised medicine that has the capacity to 
transform lives and patient care. For those with a CFTR-G551D mutation, two phase three 
trials (adult and paediatric age 6+ years) and a follow-up open label trial have demonstrated 
remarkable and sustained improvements in CFTR function, FEV1 (approximately 10% points) 
and a reduction in pulmonary exacerbations with Ivacaftor 150mg every 12-hours [1-3].  
 
From a clinical perspective it is reasonable to assume that a life-changing, life-saving oral 
medication with a simple dosing schedule would be taken as prescribed. In this issue of the 
Journal Siracusa and colleagues report important preliminary work [4] highlighting the fact 
that ‘non-adherence to Ivacaftor is a significant issue’. Their sample size was small (n=12) but 
the work has merit in having repeated assessments over three-four months. As recommended 
[5] adherence rates were obtained using multiple methods: self-report (100%), pharmacy refill 
data (medication possession ratio – 84%) and using the gold-standard of electronic 
monitoring, adherence to Ivacaftor was 61%. This appears to be a reasonable estimate as it is 
consistent with the vast literature on adherence rates. While self-report is known to generate 
higher adherence rates, 100% adherence is rare and potentially reflects the high expectation 
shouldered by patients concerning this new class of drugs. Also consistent with the literature, 
Siracusa et al. observed a decrease in the rate of adherence and an increase in the time 
between doses over time [4]. The development of this new, truly disease modifying oral 
medication provided the hope that better adherence would be a natural consequence. With 
an adherence rate of only 61% of recommended dosing, unfortunately, this is not the case. 
This has important implications in terms of clinical and patient outcomes and cost implications 
for commissioners / funders and cost-effectiveness analysis.  
 
From a behavioural science perspective these data are not surprising. For over 20 years 
adherence rates in CF have been shown to be variable and treatment-specific with many 
idiosyncratic barriers to therapies identified [6].  From follow-up phone conversations with 
patients, Siracusa et al. [4] recognised the effort required to engage patients in an ‘adherence 
dialogue’ and ascertained some patient-reported barriers (‘I forgot to take it’; ‘I do not like 
how the medication makes me feel’). Further work is essential to elicit the reasons why 
patients are unable to adhere. In the adult trial, an improvement of over 10 percentage points 
in the percent of predicted FEV1 was only accompanied by a small improvement in patient-
reported respiratory symptoms (approximately 6 points). The wide confidence intervals 
indicate that whilst some patients report moderate / large improvements, others report little 
improvement [1]. This requires unravelling.  Do these patients have more respiratory / general 
side effects? This is likely to impact on adherence and may, in part, explain why this patient-
reported outcome was less impressive than might be expected from longitudinal modelling 
[7]. Indeed, in the paediatric trial, patient/parent reported respiratory symptoms of those in 
the ivacaftor group were no better than placebo at some time points over the study period 
[2]. 
 
The efficacy and cost-effectiveness analyses of ivacaftor were calculated using an adherence 
rate of 91% [6] (returned ‘pill counts’ during the trials). This is very high and may be inflated 
given the measurement method although participation in a trial does increases adherence to 
both trial-related and nontrial-related treatment [8]. Consequently, in clinical practice, 
patients may be unlikely to attain the remarkable benefits seen in closely monitored trials. 
The NHS England estimate of the increased cost for the first year of prescribing ivacaftor to 
271 eligible patients was £43M million (61M Euro; 67M USD). The annual cost of caring for all 
7329 individuals was estimated at £150 million (214M Euro; 234M USD). Based on three 
scenarios for the longer-term effect of ivacaftor, the incremental cost-effectiveness ratio 
ranged from £335,000 to £1,274,111 (476K-1.8M Euro; 522K-2.0M USD) - for each quality-
adjusted life-year gained. The total additional lifetime costs ranged from £438 million to £479 
million (623M-681MEuro; 683M-747M USD) – the lifetime cost for standard care being £72 
million (102M Euro; 112M USD) [9]. These cost-effectiveness models provide good estimates 
based on the available data (which included the 91% adherence rate). If adherence is much 
lower the consequences of decreased clinical benefit and increased direct health costs may 
substantially alter these estimates.  
 
Access to life-transforming personalized medicines are welcome developments but 
insufficient in themselves for the successful treatment of CF disease. This new class of drugs 
has brought the adherence issue to the fore. Suboptimal health outcomes have been tolerated 
for many years with the ‘adherence issue’ put on ‘the back burner’. There has always been 
‘bigger fish to fry’ with more prestigious clinical studies to engage in. With the developments 
of Ivacaftor and Lumacaftor Moby-Dick has landed! It is time to address ‘adherence’ - a 
principal cause of treatment failure [10]. 
 
It is notable that the National Institute for Health Research (NIHR) in the UK has recently 
awarded £2 million to Wildman and colleagues to test the hypothesis, in a randomised trial, 
that novel motivational interventions will improve adherence to chronic therapies and thus 
outcomes in CF (http://www.sheffield.ac.uk/scharr/sections/hsr/mcru/actif). Previous 
interventions have been disappointing [10] but it is certainly high time for the CF community 
to put their weight behind such well designed randomised studies examining new 
interventions. 
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